Premium
The mechanisms of sulfonylurea‐induced immune hemolysis: Case report and review of the literature
Author(s) -
Kopicky Joyce A.,
Packman Charles H.
Publication year - 1986
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830230313
Subject(s) - hemolysis , medicine , chlorpropamide , sulfonylurea , hemolytic anemia , immune system , drug , anemia , immunology , coombs test , pharmacology , diabetes mellitus , antibody , endocrinology
Chlorpropamide, a sulfonylurea antidiabetic drug, was found to be the etiologic agent in a patient with immune hemolytic anemia. Hemolysis was severe, and ceased promptly when the drug was discontinued. The direct antiglobulin test was positive for complement, and the indirect antiglobulin test was also positive when the drug, patient serum, and fresh serum complement were all present. In this patient, and in four other patients described in the literature, hemolysis was mediated by the immune complex mechanism. In reports of two other patients taking a sulfonylurea drug, a milder form of hemolysis was mediated by the hapten mechanism. Sulfonylurea drugs are widely used. Since immune complex‐mediated hemolysis in these patients is dramatic, it is not likely to be missed. However, the slower, milder hemolysis mediated by the hapten mechanism may be more common than is realized. Such patients may have only mild anemia and a near‐normal reticulocyte count, making the diagnosis difficult. It is thus important to consider drug‐immune hemolysis in patients who become anemic while taking sulfonylurea drugs.